Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2years after allogeneic bone marrow transplant

Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID‐19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell‐mediated immunity is a critical component of graft...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2022-08, Vol.198 (4), p.668-679
Main Authors: Murray, Sam M, Barbanti, Maria, Campbell, Cori, Brown, Anthony, Chen, Lucia, Dhanapal, Jay, Tseu, Bing, Pervaiz, Omer, Peters, Louis, Springett, Sally, Danby, Robert, Adele, Sandra, Phillips, Eloise, Malone, Tom, Amini, Ali, Stafford, Lizzie, Deeks, Alexandra S, Dunachie, Susanna, Klenerman, Paul, Peniket, Andrew, Barnes, Eleanor, Kesavan, Murali
Format: Article
Language:English
Subjects:
Bone marrow transplantation
Coronaviruses
COVID-19
COVID-19 vaccines
Enzyme-linked immunosorbent assay
Hematology
Hematopoietic stem cells
Immunogenicity
Immunoglobulin G
Lymphocytes T
Seroconversion
Stem cell transplantation
Tumors
Vaccines
γ-Interferon
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 679
container_issue 4
container_start_page 668
container_title British journal of haematology
container_volume 198
creator Murray, Sam M
Barbanti, Maria
Campbell, Cori
Brown, Anthony
Chen, Lucia
Dhanapal, Jay
Tseu, Bing
Pervaiz, Omer
Peters, Louis
Springett, Sally
Danby, Robert
Adele, Sandra
Phillips, Eloise
Malone, Tom
Amini, Ali
Stafford, Lizzie
Deeks, Alexandra S
Dunachie, Susanna
Klenerman, Paul
Peniket, Andrew
Barnes, Eleanor
Kesavan, Murali
description Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID‐19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell‐mediated immunity is a critical component of graft‐versus‐tumour effect and in determining vaccine immunogenicity. Using validated anti‐spike (S) immunoglobulin G (IgG) and S‐specific interferon‐gamma enzyme‐linked immunospot (IFNγ‐ELIspot) assays we analysed response to a two‐dose vaccination schedule (either BNT162b2 or ChAdOx1) in 33 HSCT recipients at ≤2 years from transplant, alongside vaccine‐matched healthy controls (HCs). After two vaccines, infection‐naïve HSCT recipients had a significantly lower rate of seroconversion compared to infection‐naïve HCs (25/32 HSCT vs. 39/39 HCs no responders) and had lower S‐specific T‐cell responses. The HSCT recipients who received BNT162b2 had a higher rate of seroconversion compared to ChAdOx1 (89% vs. 74%) and significantly higher anti‐S IgG titres (p = 0.022). S‐specific T‐cell responses were seen after one vaccine in HCs and HSCT recipients. However, two vaccines enhanced S‐specific T‐cell responses in HCs but not in the majority of HSCT recipients. These data demonstrate limited immunogenicity of two‐dose vaccination strategies in HSCT recipients, bolstering evidence of the need for additional boosters and/or alternative prophylactic measures in this group.
doi_str_mv 10.1111/bjh.18312
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2699631067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2699631067</sourcerecordid><originalsourceid>FETCH-proquest_journals_26996310673</originalsourceid><addsrcrecordid>eNqNjD1Ow0AQhVcIJMJPwQ1GonbYsRMnrgOIVDSINpo4E2xrPbvMrkHpuAASZ-QkccEBeM37pPfpGXODdopj7rZdM8VlgfmJmWBRzrMcZ3hqJtbaRYZ2tjw3FzF21mJh5zgx3-s-UKu8g2bovZIDkh3U7NzgSEE5Bi-RIXkI2vakB1g9v67vf79-sIIPqutWKLVeoBUII7GkCI5jhNSQQH5g0gi0T6xAzvk3Fm5r2HphGO_Uf0JSkhgcSboyZ3tyka__-tLcPj68rJ6yoP594Jg2nR9UxmmTl1VVFmjLRfE_6wjq51vM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2699631067</pqid></control><display><type>article</type><title>Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2years after allogeneic bone marrow transplant</title><source>Wiley-Blackwell Journals</source><creator>Murray, Sam M ; Barbanti, Maria ; Campbell, Cori ; Brown, Anthony ; Chen, Lucia ; Dhanapal, Jay ; Tseu, Bing ; Pervaiz, Omer ; Peters, Louis ; Springett, Sally ; Danby, Robert ; Adele, Sandra ; Phillips, Eloise ; Malone, Tom ; Amini, Ali ; Stafford, Lizzie ; Deeks, Alexandra S ; Dunachie, Susanna ; Klenerman, Paul ; Peniket, Andrew ; Barnes, Eleanor ; Kesavan, Murali</creator><creatorcontrib>Murray, Sam M ; Barbanti, Maria ; Campbell, Cori ; Brown, Anthony ; Chen, Lucia ; Dhanapal, Jay ; Tseu, Bing ; Pervaiz, Omer ; Peters, Louis ; Springett, Sally ; Danby, Robert ; Adele, Sandra ; Phillips, Eloise ; Malone, Tom ; Amini, Ali ; Stafford, Lizzie ; Deeks, Alexandra S ; Dunachie, Susanna ; Klenerman, Paul ; Peniket, Andrew ; Barnes, Eleanor ; Kesavan, Murali</creatorcontrib><description>Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID‐19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell‐mediated immunity is a critical component of graft‐versus‐tumour effect and in determining vaccine immunogenicity. Using validated anti‐spike (S) immunoglobulin G (IgG) and S‐specific interferon‐gamma enzyme‐linked immunospot (IFNγ‐ELIspot) assays we analysed response to a two‐dose vaccination schedule (either BNT162b2 or ChAdOx1) in 33 HSCT recipients at ≤2 years from transplant, alongside vaccine‐matched healthy controls (HCs). After two vaccines, infection‐naïve HSCT recipients had a significantly lower rate of seroconversion compared to infection‐naïve HCs (25/32 HSCT vs. 39/39 HCs no responders) and had lower S‐specific T‐cell responses. The HSCT recipients who received BNT162b2 had a higher rate of seroconversion compared to ChAdOx1 (89% vs. 74%) and significantly higher anti‐S IgG titres (p = 0.022). S‐specific T‐cell responses were seen after one vaccine in HCs and HSCT recipients. However, two vaccines enhanced S‐specific T‐cell responses in HCs but not in the majority of HSCT recipients. These data demonstrate limited immunogenicity of two‐dose vaccination strategies in HSCT recipients, bolstering evidence of the need for additional boosters and/or alternative prophylactic measures in this group.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18312</identifier><language>eng</language><publisher>Oxford: Blackwell Publishing Ltd</publisher><subject>Bone marrow transplantation ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Enzyme-linked immunosorbent assay ; Hematology ; Hematopoietic stem cells ; Immunogenicity ; Immunoglobulin G ; Lymphocytes T ; Seroconversion ; Stem cell transplantation ; Tumors ; Vaccines ; γ-Interferon</subject><ispartof>British journal of haematology, 2022-08, Vol.198 (4), p.668-679</ispartof><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Murray, Sam M</creatorcontrib><creatorcontrib>Barbanti, Maria</creatorcontrib><creatorcontrib>Campbell, Cori</creatorcontrib><creatorcontrib>Brown, Anthony</creatorcontrib><creatorcontrib>Chen, Lucia</creatorcontrib><creatorcontrib>Dhanapal, Jay</creatorcontrib><creatorcontrib>Tseu, Bing</creatorcontrib><creatorcontrib>Pervaiz, Omer</creatorcontrib><creatorcontrib>Peters, Louis</creatorcontrib><creatorcontrib>Springett, Sally</creatorcontrib><creatorcontrib>Danby, Robert</creatorcontrib><creatorcontrib>Adele, Sandra</creatorcontrib><creatorcontrib>Phillips, Eloise</creatorcontrib><creatorcontrib>Malone, Tom</creatorcontrib><creatorcontrib>Amini, Ali</creatorcontrib><creatorcontrib>Stafford, Lizzie</creatorcontrib><creatorcontrib>Deeks, Alexandra S</creatorcontrib><creatorcontrib>Dunachie, Susanna</creatorcontrib><creatorcontrib>Klenerman, Paul</creatorcontrib><creatorcontrib>Peniket, Andrew</creatorcontrib><creatorcontrib>Barnes, Eleanor</creatorcontrib><creatorcontrib>Kesavan, Murali</creatorcontrib><title>Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2years after allogeneic bone marrow transplant</title><title>British journal of haematology</title><description>Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID‐19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell‐mediated immunity is a critical component of graft‐versus‐tumour effect and in determining vaccine immunogenicity. Using validated anti‐spike (S) immunoglobulin G (IgG) and S‐specific interferon‐gamma enzyme‐linked immunospot (IFNγ‐ELIspot) assays we analysed response to a two‐dose vaccination schedule (either BNT162b2 or ChAdOx1) in 33 HSCT recipients at ≤2 years from transplant, alongside vaccine‐matched healthy controls (HCs). After two vaccines, infection‐naïve HSCT recipients had a significantly lower rate of seroconversion compared to infection‐naïve HCs (25/32 HSCT vs. 39/39 HCs no responders) and had lower S‐specific T‐cell responses. The HSCT recipients who received BNT162b2 had a higher rate of seroconversion compared to ChAdOx1 (89% vs. 74%) and significantly higher anti‐S IgG titres (p = 0.022). S‐specific T‐cell responses were seen after one vaccine in HCs and HSCT recipients. However, two vaccines enhanced S‐specific T‐cell responses in HCs but not in the majority of HSCT recipients. These data demonstrate limited immunogenicity of two‐dose vaccination strategies in HSCT recipients, bolstering evidence of the need for additional boosters and/or alternative prophylactic measures in this group.</description><subject>Bone marrow transplantation</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G</subject><subject>Lymphocytes T</subject><subject>Seroconversion</subject><subject>Stem cell transplantation</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>γ-Interferon</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNjD1Ow0AQhVcIJMJPwQ1GonbYsRMnrgOIVDSINpo4E2xrPbvMrkHpuAASZ-QkccEBeM37pPfpGXODdopj7rZdM8VlgfmJmWBRzrMcZ3hqJtbaRYZ2tjw3FzF21mJh5zgx3-s-UKu8g2bovZIDkh3U7NzgSEE5Bi-RIXkI2vakB1g9v67vf79-sIIPqutWKLVeoBUII7GkCI5jhNSQQH5g0gi0T6xAzvk3Fm5r2HphGO_Uf0JSkhgcSboyZ3tyka__-tLcPj68rJ6yoP594Jg2nR9UxmmTl1VVFmjLRfE_6wjq51vM</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Murray, Sam M</creator><creator>Barbanti, Maria</creator><creator>Campbell, Cori</creator><creator>Brown, Anthony</creator><creator>Chen, Lucia</creator><creator>Dhanapal, Jay</creator><creator>Tseu, Bing</creator><creator>Pervaiz, Omer</creator><creator>Peters, Louis</creator><creator>Springett, Sally</creator><creator>Danby, Robert</creator><creator>Adele, Sandra</creator><creator>Phillips, Eloise</creator><creator>Malone, Tom</creator><creator>Amini, Ali</creator><creator>Stafford, Lizzie</creator><creator>Deeks, Alexandra S</creator><creator>Dunachie, Susanna</creator><creator>Klenerman, Paul</creator><creator>Peniket, Andrew</creator><creator>Barnes, Eleanor</creator><creator>Kesavan, Murali</creator><general>Blackwell Publishing Ltd</general><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20220801</creationdate><title>Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2years after allogeneic bone marrow transplant</title><author>Murray, Sam M ; Barbanti, Maria ; Campbell, Cori ; Brown, Anthony ; Chen, Lucia ; Dhanapal, Jay ; Tseu, Bing ; Pervaiz, Omer ; Peters, Louis ; Springett, Sally ; Danby, Robert ; Adele, Sandra ; Phillips, Eloise ; Malone, Tom ; Amini, Ali ; Stafford, Lizzie ; Deeks, Alexandra S ; Dunachie, Susanna ; Klenerman, Paul ; Peniket, Andrew ; Barnes, Eleanor ; Kesavan, Murali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_26996310673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bone marrow transplantation</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G</topic><topic>Lymphocytes T</topic><topic>Seroconversion</topic><topic>Stem cell transplantation</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murray, Sam M</creatorcontrib><creatorcontrib>Barbanti, Maria</creatorcontrib><creatorcontrib>Campbell, Cori</creatorcontrib><creatorcontrib>Brown, Anthony</creatorcontrib><creatorcontrib>Chen, Lucia</creatorcontrib><creatorcontrib>Dhanapal, Jay</creatorcontrib><creatorcontrib>Tseu, Bing</creatorcontrib><creatorcontrib>Pervaiz, Omer</creatorcontrib><creatorcontrib>Peters, Louis</creatorcontrib><creatorcontrib>Springett, Sally</creatorcontrib><creatorcontrib>Danby, Robert</creatorcontrib><creatorcontrib>Adele, Sandra</creatorcontrib><creatorcontrib>Phillips, Eloise</creatorcontrib><creatorcontrib>Malone, Tom</creatorcontrib><creatorcontrib>Amini, Ali</creatorcontrib><creatorcontrib>Stafford, Lizzie</creatorcontrib><creatorcontrib>Deeks, Alexandra S</creatorcontrib><creatorcontrib>Dunachie, Susanna</creatorcontrib><creatorcontrib>Klenerman, Paul</creatorcontrib><creatorcontrib>Peniket, Andrew</creatorcontrib><creatorcontrib>Barnes, Eleanor</creatorcontrib><creatorcontrib>Kesavan, Murali</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murray, Sam M</au><au>Barbanti, Maria</au><au>Campbell, Cori</au><au>Brown, Anthony</au><au>Chen, Lucia</au><au>Dhanapal, Jay</au><au>Tseu, Bing</au><au>Pervaiz, Omer</au><au>Peters, Louis</au><au>Springett, Sally</au><au>Danby, Robert</au><au>Adele, Sandra</au><au>Phillips, Eloise</au><au>Malone, Tom</au><au>Amini, Ali</au><au>Stafford, Lizzie</au><au>Deeks, Alexandra S</au><au>Dunachie, Susanna</au><au>Klenerman, Paul</au><au>Peniket, Andrew</au><au>Barnes, Eleanor</au><au>Kesavan, Murali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2years after allogeneic bone marrow transplant</atitle><jtitle>British journal of haematology</jtitle><date>2022-08-01</date><risdate>2022</risdate><volume>198</volume><issue>4</issue><spage>668</spage><epage>679</epage><pages>668-679</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Allogeneic haematopoietic stem cell transplant (HSCT) recipients remain at high risk of adverse outcomes from coronavirus disease 2019 (COVID‐19) and emerging variants. The optimal prophylactic vaccine strategy for this cohort is not defined. T cell‐mediated immunity is a critical component of graft‐versus‐tumour effect and in determining vaccine immunogenicity. Using validated anti‐spike (S) immunoglobulin G (IgG) and S‐specific interferon‐gamma enzyme‐linked immunospot (IFNγ‐ELIspot) assays we analysed response to a two‐dose vaccination schedule (either BNT162b2 or ChAdOx1) in 33 HSCT recipients at ≤2 years from transplant, alongside vaccine‐matched healthy controls (HCs). After two vaccines, infection‐naïve HSCT recipients had a significantly lower rate of seroconversion compared to infection‐naïve HCs (25/32 HSCT vs. 39/39 HCs no responders) and had lower S‐specific T‐cell responses. The HSCT recipients who received BNT162b2 had a higher rate of seroconversion compared to ChAdOx1 (89% vs. 74%) and significantly higher anti‐S IgG titres (p = 0.022). S‐specific T‐cell responses were seen after one vaccine in HCs and HSCT recipients. However, two vaccines enhanced S‐specific T‐cell responses in HCs but not in the majority of HSCT recipients. These data demonstrate limited immunogenicity of two‐dose vaccination strategies in HSCT recipients, bolstering evidence of the need for additional boosters and/or alternative prophylactic measures in this group.</abstract><cop>Oxford</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/bjh.18312</doi></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2022-08, Vol.198 (4), p.668-679
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_journals_2699631067
source Wiley-Blackwell Journals
subjects Bone marrow transplantation
Coronaviruses
COVID-19
COVID-19 vaccines
Enzyme-linked immunosorbent assay
Hematology
Hematopoietic stem cells
Immunogenicity
Immunoglobulin G
Lymphocytes T
Seroconversion
Stem cell transplantation
Tumors
Vaccines
γ-Interferon
title Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2years after allogeneic bone marrow transplant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A46%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impaired%20humoral%20and%20cellular%20response%20to%20primary%20COVID%E2%80%9019%20vaccination%20in%20patients%20less%20than%202years%20after%20allogeneic%20bone%20marrow%20transplant&rft.jtitle=British%20journal%20of%20haematology&rft.au=Murray,%20Sam%20M&rft.date=2022-08-01&rft.volume=198&rft.issue=4&rft.spage=668&rft.epage=679&rft.pages=668-679&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18312&rft_dat=%3Cproquest%3E2699631067%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_26996310673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2699631067&rft_id=info:pmid/&rfr_iscdi=true